102 related articles for article (PubMed ID: 25672893)
1. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis.
Janssen-Heijnen MLG; van Erning FN; De Ruysscher DK; Coebergh JWW; Groen HJM
Ann Oncol; 2015 May; 26(5):902-907. PubMed ID: 25672893
[TBL] [Abstract][Full Text] [Related]
2. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
[TBL] [Abstract][Full Text] [Related]
3. "Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study".
Soto-Campos JG; Plaza V; Soriano JB; Cabrera-López C; Almonacid-Sánchez C; Vazquez-Oliva R; Serrano J; Ballaz-Quincoces A; Padilla-Galo A; Santos V;
BMC Pulm Med; 2013 Dec; 13():73. PubMed ID: 24321217
[TBL] [Abstract][Full Text] [Related]
4. Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party.
Berghmans T; Ameye L; Lafitte JJ; Colinet B; Cortot A; CsToth I; Holbrechts S; Lecomte J; Mascaux C; Meert AP; Paesmans M; Richez M; Scherpereel A; Tulippe C; Willems L; Dernies T; Leclercq N; Sculier JP;
Front Oncol; 2014; 4():386. PubMed ID: 25674536
[TBL] [Abstract][Full Text] [Related]
5. The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis.
Jiang L; Liang W; Shen J; Chen X; Shi X; He J; Yang C; He J
Chest; 2015 Oct; 148(4):903-911. PubMed ID: 25675151
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
[TBL] [Abstract][Full Text] [Related]
7. Squamous non-small cell lung cancer as a distinct clinical entity.
Oliver TG; Patel J; Akerley W
Am J Clin Oncol; 2015 Apr; 38(2):220-6. PubMed ID: 25806712
[TBL] [Abstract][Full Text] [Related]
8. Treatment Toxicity in Elderly Patients With Advanced Non-Small Cell Lung Cancer.
Kale MS; Mhango G; Gomez JE; Sigel K; Smith CB; Bonomi M; Wisnivesky JP
Am J Clin Oncol; 2017 Oct; 40(5):470-476. PubMed ID: 25784564
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for cases with no extracranial metastasis in whom brain metastasis is detected after resection of non-small cell lung cancer.
Bae MK; Yu WS; Byun GE; Lee CY; Lee JG; Kim DJ; Chung KY
Lung Cancer; 2015 May; 88(2):195-200. PubMed ID: 25770646
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA
Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952
[TBL] [Abstract][Full Text] [Related]
12. Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 study.
Bruce N; Dherani M; Liu R; Hosgood HD; Sapkota A; Smith KR; Straif K; Lan Q; Pope D
Thorax; 2015 May; 70(5):433-41. PubMed ID: 25758120
[TBL] [Abstract][Full Text] [Related]
13. Associations between driver gene mutations and cytotoxic chemosensitivity in patients with non-small cell lung cancer.
Morodomi Y; Okamoto T; Kohno M; Katsura M; Takada K; Suzuki Y; Fujishita T; Kitahara H; Shimamatsu S; Yoshida T; Tagawa T; Okano S; Maehara Y
Anticancer Res; 2015 Mar; 35(3):1791-6. PubMed ID: 25750344
[TBL] [Abstract][Full Text] [Related]
14. Fruit and vegetable consumption and risk of lung cancer: a dose-response meta-analysis of prospective cohort studies.
Wang Y; Li F; Wang Z; Qiu T; Shen Y; Wang M
Lung Cancer; 2015 May; 88(2):124-30. PubMed ID: 25747805
[TBL] [Abstract][Full Text] [Related]
15. No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Couraud S; Debieuvre D; Moreau L; Dumont P; Margery J; Quoix E; Duvert B; Cellerin L; Baize N; Taviot B; Coudurier M; Cadranel J; Missy P; Morin F; Mornex JF; Zalcman G; Souquet PJ;
Eur Respir J; 2015 May; 45(5):1415-25. PubMed ID: 25745045
[TBL] [Abstract][Full Text] [Related]
16. Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.
Timmers L; Boons CC; Moes-Ten Hove J; Smit EF; van de Ven PM; Aerts JG; Swart EL; Boven E; Hugtenburg JG
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1481-91. PubMed ID: 25743274
[TBL] [Abstract][Full Text] [Related]
17. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit.
Rich AL; Khakwani A; Free CM; Tata LJ; Stanley RA; Peake MD; Hubbard RB; Baldwin DR
QJM; 2015 Nov; 108(11):891-7. PubMed ID: 25725079
[TBL] [Abstract][Full Text] [Related]
18. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C; Wang Z; Sun Y; Cao L; Ma Z; Wu R; Yu Y; Yao W; Chang J; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Wang J; Li P; Qin M; Lu D; Yang J
Lancet Oncol; 2022 Feb; 23(2):220-233. PubMed ID: 35038432
[TBL] [Abstract][Full Text] [Related]
19. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S; Chen J; Xu X; Jiang T; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Yang Z; Shi W; Zou J; Zhou C;
J Thorac Oncol; 2022 Apr; 17(4):544-557. PubMed ID: 34923163
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
